Suchergebnisse - "Hou, Mimi M"

PubPharm (11)

1

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development

enthalten in: Vaccine | 2024

von Mertens, J. | Rigby, C. | Bardelli, M. | +10

2

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial

enthalten in: NPJ vaccines | 2024

von Martinez, F. | White, M. | Guillotte-Blisnick, M. | +15

3

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

enthalten in: Science translational medicine | 2023

von Hou, M. | Barrett, J. | Themistocleous, Y. | +33

UpdateOf: medRxiv. 2022 May 30;:. - PMID 35664997

4

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

enthalten in: Frontiers in immunology | 2023

von Barrett, J. | Silk, S. | Mkindi, C. | +18

5

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum : Safety and parasite growth dynamics

enthalten in: Frontiers in immunology | 2022

von Salkeld, J. | Themistocleous, Y. | Barrett, J. | +24

6

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) : a single-blind, randomised, controlled, phase 2/3 trial

enthalten in: Lancet (London, England) | 2021

von Ramasamy, M. | Minassian, A. | Ewer, K. | +162

ErratumIn: Lancet. 2021 Dec 19;396(10267):1978. - PMID 33341142

7

Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly

enthalten in: JCI insight | 2021

von Minassian, A. | Themistocleous, Y. | Silk, S. | +42

8

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

enthalten in: Nature communications | 2021

von Clemens, S. | Folegatti, P. | Emary, K. | +125

9

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK : a substudy of two randomised controlled trials (COV001 and COV002)

enthalten in: Lancet (London, England) | 2021

von Flaxman, A. | Marchevsky, N. | Jenkin, D. | +135

CommentIn: Lancet. 2021 Sep 11;398(10304):933-935. - PMID 34480860

10

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

enthalten in: Nature medicine | 2021

von Barrett, J. | Belij-Rammerstorfer, S. | Dold, C. | +152

CommentIn: Nat Rev Immunol. 2021 Feb;21(2):70-71. - PMID 33432129